Streptococcus pneumoniae is the most common cause of community-acquired bacterial pneumonia (29) , and mortality from bacteremic infections remains high despite the use of appropriate antibiotics, intensive care support, and immunization (23, 27, 28, 30) . Pneumolysin, an oxygen-labile pneumococcal cytolysin, appears to be a virulence factor in pneumococcal pneumonia (for review, see reference 7). Pneumolysin's cytolytic activity has been attributed to its ability to bind membrane cholesterol and form transmembrane pore complexes (1) . Pneumolysin is capable of directly injuring bronchial epithelial cells (40) , alveolar epithelial cells (36) , and pulmonary arterial endothelial cells (35) . Subsequent disruption of the cells constituting the alveolar-capillary barrier, which is the principal barrier to leakage of fluid and solute into the alveoli (8, 45) , may account for much of the histopathology typical of early pneumococcal pneumonia, such as alveolar flooding and hemorrhage (46) . Pneumolysin may also play a role in pneumococcal pneumonia by contributing to the development of the acute inflammatory response. Pneumolysin has been implicated in this type of inflammatory response by virtue of its ability to activate the classical pathway of complement (31) . However, complement activation occurs only at relatively high concentrations of pneumolysin. Furthermore, the ability of genetically modified pneumolysins to elicit a lung inflammatory response correlates more closely with their cytolytic activities than with their complement-activating potential (17) . As yet, mechanisms by which pneumolysin-mediated tissue injury might evoke an acute inflammatory response in the lung have not been explored.
Lipid mediators, particularly products of arachidonic acid metabolism and platelet-activating factor, have powerful * Corresponding author. Mailing address: Pulmonary (1l1N), Min- proinflammatory activity. In lungs, the arachidonic acid pathway has been shown to be a major source of neutrophil chemotaxins during pneumococcal infection (43) . Therefore, we speculated that pneumolysin-induced injury might activate cellular phospholipases, which might provide a substrate for the generation of proinflammatory products. Activation of phospholipases is suggested by early studies of the actions of pneumolysin on erythrocytes. In contrast to osmotic lysis, in which erythrocyte membranes are well preserved, exposure to pneumolysin causes complete dissolution of the membranes (26) , suggesting that cellular hydrolases have been activated. Moreover, lung tissue injury from a variety of other causes is associated with increased cellular phospholipase activity (25, 33, 38) .
A variety of phospholipases are present in all mammalian cells, and they are classified according to their site of action on the diacylated phospholipid. Phospholipases A1 and A2 hydrolyze sn-1 and sn-2 fatty acyl bonds, respectively, generating free fatty acids (FFA) and lysophosphatides; phospholipase C hydrolyzes the sn-3 phosphate ester bond, yielding diacylglyceride and a phosphorylated head group; and phospholipase D cleaves the second phosphate ester bond, producing phosphatidic acid and a free head group (Fig. 1 ). Diacylglycerol and phosphatidic acid can be further metabolized via several pathways to also yield FFA. In addition to the "housekeeping" tasks of regulating phospholipid synthesis and turnover via deacylation-reacylation cycles, phospholipases have been implicated in a variety of other vital cellular functions, principally by the generation of various phospholipid-derived mediators.
In the present study, we demonstrate for the first time that pneumolysin is a potent activator of cellular phospholipase(s) in lung endothelial cells. We Pneumolysin purification. Native pneumolysin was purified by a modification of previously described methods (22) . Briefly, type 14 pneumococci (ATCC 6314) were grown to log phase in brain heart infusion broth. Washed bacteria resuspended at approximately 1010 CFU/ml in lysis buffer (PBS containing 0.2 mM phenylmethylsulfonyl fluoride, 5 mM dithiothreitol, and 0.25 mg of DNase I per ml) were disrupted at 4°C in a French pressure cell (25,000 lb/in2) (SLM Instruments, Urbana, Ill.). After centrifugation, proteins were precipitated from the supernatant first by acidification with 1 N glacial acetic acid and then after resuspension in 60 ml of 0.2 M sodium phosphate (pH 7.0), by 58% saturation with ammonium sulfate. Precipitated proteins were resuspended in 50 mM NaCl-10 mM Tris-HCl (pH 8.0) and dialyzed overnight against the same buffer. The dialyzed lysate (50 ml) was applied to a Phenyl-Sepharose CL-4B column (2.5 by 20 cm) equilibrated with the same buffer, washed with 100 ml of 5 mM NaCl-5 mM sodium phosphate followed by 100 ml of 1 mM NaCl-1 mM sodium phosphate, and eluted with 100 ml of deionized water. Fractions with hemolytic activity were pooled (50 ml), applied to a hydroxylapatite column (1.5 by 40 cm) equilibrated with 10 mM sodium phosphate (pH 7.0), and eluted with a linear gradient from 10 to 240 mM sodium phosphate. The peak of hemolytic activity (30 ml) was concentrated 10-fold by ultrafiltration (PM-10 filter; Amicon, Beverly, Mass.), applied to a Sephacryl S-200 column (1.5 by 120 cm) equilibrated with PBS containing 1 mM dithiothreitol, and eluted in the same buffer into 3-ml fractions. Fractions containing hemolytic activity were pooled and frozen in aliquots at -200C.
Recombinant pneumolysins were purified from lysates of Escherichia coli JM109 harboring the pneumolysin gene in the expression vector pKK233-2 by hydrophobic chromatography on a TSK phenyl-5PW high-pressure liquid chromatography column (24) .
Each of the two purified toxins migrated as a single band with an approximate molecular mass of 53 kDa on silverstained sodium dodecyl sulfate-polyacrylamide gels and had specific activities of 3 x 105 (native pneumolysin) and 3 X 106 (recombinant pneumolysin) hemolytic units per mg of protein, assayed as previously described (36 Genetically modified pneumolysin toxins were previously prepared by oligonucleotide-mediated, site-directed mutagenesis as described previously (37) . Substitution of tryptophan 433 with phenylalanine (Trp-433--*Phe) and substitution of the single cysteine residue at position 428 with serine (Cys-428--Ser) or glycine (Cys-428->Gly) produced toxins with decreased hemolytic activities but with apparently normal formation of membrane oligomers (17, 37) .
Cytotoxicity assay. Cytotoxicity assays of endothelial cells were performed as described elsewhere (35) . Briefly, cells were radiolabeled overnight with sodium [51Cr]chromate, washed three times with PBS, and incubated in assay buffer (PBS, 5% bovine serum albumin, 2% dextrose) with or without pneumolysin at 37°C for varying times. The medium was removed and centrifuged at 500 x g for 10 min, and the radioactivity of an aliquot of the supernatant was measured by liquid scintillation (Packard 1900 CA Tri Carb). To determine the remaining cellular 51Cr, the pellet and cell monolayer were dissolved in 2 N NaOH and mixed and the radioactivity of an aliquot was counted. separated by one-dimensional TLC on Silica G60 plates with a solvent system consisting of chloroform-acetone-methanolacetic acid-water (120:60:30:30:15). Phosphatidic acid and phosphatidylethanol were separated in a solvent system consisting of the upper phase of a mixture of ethyl acetateisooctane-acetic acid-water (110:50:37.5:100). Arachidonic acid, diacylglycerol, and monoacylglycerol were separated in ether-hexane-glacial acetic acid (50:50:1). Choline, phosphocholine, and glycerophosphocholine from the aqueous phases of ['4C]choline-labeled cells were separated on Silica G60 plates with methanol-0.5% NaCl-ammonium hydroxide (100: 100:2). Chromatograms were developed with authentic standards, and spots were identified by iodine vapor or by lightly spraying the plates with 2,7-dichlorofluorescein. Spots were scraped, and the disintegrations per minute for each spot was determined by liquid scintillation spectroscopy. All results are expressed as the percentage of radioactivity recovered relative to the total radioactivity in each well.
Phospholipase A assay. Biosynthetically radiolabeled substrate was prepared by incubating near-confluent monolayers of BPAEC (100-mm-diameter wells) with 2. (Fig. 3) . The same concentration of pneumolysin produced a similarly rapid release of 51Cr, with a time course parallel to that of [3H]AA (Fig. 3) . Thus, pneumolysin-induced cytotoxicity appeared to be closely associated with accelerated phospholipid hydrolysis and release of arachidonic acid in these studies. Table 4 , roughly equivalent cell injuries from these lytic agents are associated with widely varying degrees of [3H]AA release. The most notable example is streptolysin S, which produced appreciable cellular injury but only a minimal increase in phospholipase activity. Thus, phospholipase A activation was not an invariable consequence of cell membrane disruption.
Finally, we noted that the genetically modified pneumolysins which form nonfunctional oligomeric complexes in membranes (37) did not stimulate phospholipase A activity (Table 3) . Thus, these studies indicated that pneumolysin binding to and aggregation in cellular membranes is not sufficient to activate phospholipase A and suggested that the formation of functional transmembrane pores might be a necessary event.
Effect of extracellular [Ca2+] on pneumolysin-stimulated phospholipase A activity. Most forms of phospholipase A exhibit an absolute Ca2" dependence (44) . Therefore, pneumolysin transmembrane pore complexes might activate phos- Activation of exogenous phospholipase A2 by pneumolysin.
Certain lytic toxins, particularly mellitin and mastoparan, stimulate the activity of some purified phospholipase A2s, presumably via their ability to alter the physical state of the substrate (3, 47) . Since pneumolysin is also an amphipathic protein, we postulated that it might produce similar effects. We assayed phospholipase A2s purified from bee venom, snake (Naja naja) venom, and porcine pancreas against [3H]AAlabeled phospholipids isolated from BPAEC in the presence of various concentrations of pneumolysin. Phospholipase A2 activities were normalized to the concentrations of enzymes required to hydrolyze 10 to 15% of substrate in 60 min at 37°C. Pneumolysin had a pronounced stimulating effect on bee venom phospholipase A2 activity, a small stimulating effect on snake venom phospholipase A2 activity, and an inhibitory effect on pancreatic phospholipase A2 activity (Fig. 6) . Thus, pneumolysin is capable of activating specific purified phospholipase A2s in vitro and may directly interact with cellular phospholipase A.
DISCUSSION
We have shown for the first time that pneumolysin rapidly and potently activates cellular phospholipases, which may generate lipid products that contribute both to direct lung injury and to the inflammatory response in pneumococcal [pneumolysin], jig/ml (41) , neither the mechanism of activation nor the specific pathways of arachidonic acid liberation by these toxins have been clearly delineated.
Our studies reveal that pneumolysin activates primarily phospholipase A, presumably phospholipase A2. Although pneumolysin-induced membrane injury and pneumolysin-stimulated phospholipase A activity were closely coupled in time and dose experiments, intact pneumolysin lytic activity appeared to be necessary for the activation of phospholipase A. In contrast, pneumolysin cytolytic activity was preserved despite the inhibition of detectable phospholipase A activity by bromophenacyl bromide or manoalide, indicating that the assembly of a functioning pneumolysin transmembrane pore complex does not require the activation of cellular phospholipase A.
Phospholipase A activation by pneumolysin may release cytotoxic products, such as FFA and lysophosphatides, that in turn magnify the lung injury produced during pneumococcal pneumonia. Experimental studies indicate that the epithelial and endothelial cells forming the blood-gas barrier of a lung are highly susceptible to certain hydrolytic products of phospholipases. The intravenous administration of oleic acid and intratracheal administration of lysophosphatidylcholine cause extensive damage to the alveolar epithelium and the capillary endothelium, not unlike morphologic changes in the adult respiratory distress syndrome (25) (13, 33, 38) .
The activation of phospholipase A by pneumolysin might also contribute to lung tissue injury by generating inflammatory lipid mediators. Arachidonic acid released by phospholipase A is capable of directly evoking chemotaxis and a respiratory burst in neutrophils (4, 5, 12) . Also, arachidonic acid released from injured endothelial cells might be taken up and further metabolized by intact endothelial cells or some other cell type within the micromilieu of an intact lung. Arachidonic acid can be metabolized through the eicosanoid cascade, with production of leukotrienes and 1-O-alkyl-2-hydroxy-sn-glycero-3-phosphocholine, the precursor of platelet-activating factor (20, 32) . Products of the eicosanoid cascade, in addition to platelet-activating factor, have been shown to be a major pulmonary source of neutrophil chemotaxins in a rabbit model of experimental pneumonitis (9, 43) . Subsequent recruitment and activation of polymorphonuclear cells may injure lung epithelial and endothelial cells by the release of reactive oxygen species and proteases (42) . Thus, the activation of phospholipase A by pneumolysin might underlie the connection between pneumolysin's cytolytic activity and its ability to evoke an inflammatory response in studies of experimental pneumonitis (17) . (3, 11, 47) . The facilitating mechanism is not fully understood, but these agents likely induce critical changes in the physical state of the substrate, allowing the enzyme greater accessibility to the phospholipids. Not surprisingly, effects from "chaotropic" agents appear to be both enzyme-and substrate-specific (3, 47) , so caution must be exercised in extrapolating results obtained from acellular assay systems to events occurring in an intact cell. Nonetheless, a mellitin-like interaction with membrane phospholipids appears to be the most plausible explanation for the potent phospholipase A-stimulating effects of pneumolysin in BPAEC.
